• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MSPDBL2基因第591位密码子多态性与肯尼亚基利菲恶性疟原虫分离株中卤泛群的体外药物反应相关。

The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.

作者信息

Ochola-Oyier Lynette Isabella, Okombo John, Mwai Leah, Kiara Steven M, Pole Lewa, Tetteh Kevin K A, Nzila Alexis, Marsh Kevin

机构信息

Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya

Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.

出版信息

Antimicrob Agents Chemother. 2015 Mar;59(3):1770-5. doi: 10.1128/AAC.03522-14. Epub 2014 Dec 22.

DOI:10.1128/AAC.03522-14
PMID:25534732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4325780/
Abstract

The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P = 0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).

摘要

恶性疟原虫对通常与青蒿素联合使用的卤泛群（LUM）产生耐药性的机制仍不清楚。我们评估了肯尼亚人群中Pfmspdbl2的多态性与卤泛群活性的相关性。MSPDBL2密码子591S与对卤泛群的敏感性降低相关（P = 0.04）。肯尼亚Pfmspdbl2密码子591S的高频率可能是由于卤泛群在青蒿素联合疗法（科泰复）中的广泛使用所致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9661/4325780/a67ddb6db816/zac0031537550002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9661/4325780/128c323274a7/zac003153755001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9661/4325780/a67ddb6db816/zac0031537550002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9661/4325780/128c323274a7/zac003153755001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9661/4325780/a67ddb6db816/zac0031537550002.jpg

相似文献

1
The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.MSPDBL2基因第591位密码子多态性与肯尼亚基利菲恶性疟原虫分离株中卤泛群的体外药物反应相关。
Antimicrob Agents Chemother. 2015 Mar;59(3):1770-5. doi: 10.1128/AAC.03522-14. Epub 2014 Dec 22.
2
Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.哥伦比亚三个疟疾流行区恶性疟原虫对蒿甲醚和本芴醇的基线体内、体外及分子反应
Trans R Soc Trop Med Hyg. 2017 Feb 1;111(2):71-80. doi: 10.1093/trstmh/trx021.
3
K13-Propeller Polymorphisms in Plasmodium falciparum Isolates from Patients in Mayotte in 2013 and 2014.2013年和2014年马约特岛患者恶性疟原虫分离株中的K13螺旋桨多态性
Antimicrob Agents Chemother. 2015 Dec;59(12):7878-81. doi: 10.1128/AAC.01251-15. Epub 2015 Sep 28.
4
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).蒿甲醚-本芴醇（复方蒿甲醚）对恶性疟原虫pfmdr1 86N编码等位基因的体内选择
J Infect Dis. 2005 Mar 15;191(6):1014-7. doi: 10.1086/427997. Epub 2005 Feb 8.
5
Modulation of PF10_0355 (MSPDBL2) alters Plasmodium falciparum response to antimalarial drugs.PF10_0355（MSPDBL2）的调控改变了恶性疟原虫对抗疟药物的反应。
Antimicrob Agents Chemother. 2013 Jul;57(7):2937-41. doi: 10.1128/AAC.02574-12. Epub 2013 Apr 15.
6
Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance.恶性疟原虫 ABC 转运蛋白基因的新型多态性与主要 ACT 抗疟药物耐药性相关。
PLoS One. 2011;6(5):e20212. doi: 10.1371/journal.pone.0020212. Epub 2011 May 25.
7
Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania.坦桑尼亚巴加莫约地区与青蒿琥酯-咯萘啶耐药性相关的分子标志物的时间趋势。
Malar J. 2013 Mar 18;12:103. doi: 10.1186/1475-2875-12-103.
8
Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya.肯尼亚西部接受蒿甲醚-本芴醇治疗前和治疗后疟原虫中，恶性疟原虫分子标记物流行率的时间趋势。
Int J Parasitol Drugs Drug Resist. 2015 Jun 29;5(3):92-9. doi: 10.1016/j.ijpddr.2015.05.005. eCollection 2015 Dec.
9
Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum.pfmdr1 基因与体外青蒿素和咯萘啶敏感性在泰国恶性疟原虫分离株中的关系。
Am J Trop Med Hyg. 2010 Nov;83(5):1005-9. doi: 10.4269/ajtmh.2010.10-0339.
10
Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine.在法国城市加蓬的班古替换氯喹为青蒿琥酯-咯萘啶和青蒿琥酯-甲氟喹后，恶性疟原虫 Pfmdr1 86N 基因型的流行率增加。
Infect Genet Evol. 2011 Mar;11(2):512-7. doi: 10.1016/j.meegid.2011.01.003. Epub 2011 Jan 17.

引用本文的文献

1
Expression of the MSPDBL2 antigen in a discrete subset of schizonts is regulated by GDV1 but may not be linked to sexual commitment.MSPDBL2 抗原在裂殖子的一个离散亚群中的表达受 GDV1 调控，但可能与有性发育无关。
mBio. 2024 May 8;15(5):e0314023. doi: 10.1128/mbio.03140-23. Epub 2024 Mar 26.
2
Comparison of allele frequencies of Plasmodium falciparum merozoite antigens in malaria infections sampled in different years in a Kenyan population.肯尼亚人群中不同年份采集的疟疾感染样本中恶性疟原虫裂殖子抗原等位基因频率的比较。
Malar J. 2016 May 6;15(1):261. doi: 10.1186/s12936-016-1304-8.

本文引用的文献

1
Modulation of PF10_0355 (MSPDBL2) alters Plasmodium falciparum response to antimalarial drugs.PF10_0355（MSPDBL2）的调控改变了恶性疟原虫对抗疟药物的反应。
Antimicrob Agents Chemother. 2013 Jul;57(7):2937-41. doi: 10.1128/AAC.02574-12. Epub 2013 Apr 15.
2
Insights into Duffy binding-like domains through the crystal structure and function of the merozoite surface protein MSPDBL2 from Plasmodium falciparum.通过疟原虫裂殖子表面蛋白 MSPDBL2 的晶体结构和功能深入了解达菲结合样结构域。
J Biol Chem. 2012 Sep 21;287(39):32922-39. doi: 10.1074/jbc.M112.350504. Epub 2012 Jul 26.
3
Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.
体内耐受性和体外抗疟药青蒿琥酯敏感性降低的最新研究进展。
J Antimicrob Chemother. 2012 Oct;67(10):2309-15. doi: 10.1093/jac/dks252. Epub 2012 Jul 2.
4
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.肯尼亚分离疟原虫株中奎宁和其他抗疟药物的体外活性与 pfnep 多态性。
Antimicrob Agents Chemother. 2010 Aug;54(8):3302-7. doi: 10.1128/AAC.00325-10. Epub 2010 Jun 1.
5
Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum.基于等位基因频率和多态性与分歧指数的疟原虫新过滤多态基因中的平衡选择。
Mol Biol Evol. 2010 Oct;27(10):2344-51. doi: 10.1093/molbev/msq119. Epub 2010 May 9.
6
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.在肯尼亚恶性疟原虫分离株中哌喹、青蒿琥酯和二氢青蒿素的体外活性以及 pfcrt 和 pfmdr1 的多态性。
Antimicrob Agents Chemother. 2009 Dec;53(12):5069-73. doi: 10.1128/AAC.00638-09. Epub 2009 Sep 21.
7
A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum.一个保守的多基因家族可诱导产生对恶性疟原虫防御有效的交叉反应性抗体。
PLoS One. 2009;4(4):e5410. doi: 10.1371/journal.pone.0005410. Epub 2009 Apr 30.
8
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.在非洲用蒿甲醚-本芴醇治疗后，体内选择携带对氯喹敏感的恶性疟原虫pfcrt K76等位基因的疟原虫。
J Infect Dis. 2009 Mar 1;199(5):750-7. doi: 10.1086/596738.
9
Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria.蒿甲醚-本芴醇对尼日利亚单纯性恶性疟患儿无性期和配子体中恶性疟原虫多药耐药基因1等位基因的选择作用
Antimicrob Agents Chemother. 2009 Mar;53(3):888-95. doi: 10.1128/AAC.00968-08. Epub 2008 Dec 15.
10
The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa.pfmdr1在非洲恶性疟原虫对蒿甲醚-本芴醇耐受性中的作用。
Trop Med Int Health. 2007 Jun;12(6):736-42. doi: 10.1111/j.1365-3156.2007.01843.x.